Neal Shore, MD, discusses the current outlook for the treatment landscape in advanced or metastatic urothelial carcinoma.
Neal Shore, MD, director, Carolina Urologic Research Center, discusses the current outlook for the treatment landscape in advanced or metastatic urothelial carcinoma.
The landscape has evolved dramatically due, in part, to the increased understanding of advanced disease, which led to the approval of 5 encouraging checkpoint inhibitor therapies, and approval of other novel therapies as well. These are truly remarkable improvements, Shore says.
We have also gained improved understanding of the use of immunotherapy in the frontline, as well as in the second-line and maintenance settings for patients with metastatic urothelial carcinoma. Among other advances in the field, Shore highlights the approval of erdafitinib (Balversa) and enfortumab vedotin-ejfv (Padcev), and these therapies all provide expanded treatment options for patients with metastatic disease who either failed or weren’t candidates for radical cystectomy.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More
Nivolumab With Gemcitabine-Cisplatin Boosts Survival in Metastatic Urothelial Carcinoma
May 5th 2024Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.
Read More